Effectiveness of rituximab in severe Wegener's granulomatosis: Report of two cases and review of the literature

Open Respiratory Medicine Journal

Volumn 3, Issue , 2009, Pages 94-99

  Oristrell, Joaquim ^a   Bejarano, Guillermina ^a   Jordana, Rosa ^a   Monteagudo, Manuel ^a   Marí, Begoña ^a   Casanovas, Arnau ^a   Tolosa, Carles ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Rescue treatment; Rituximab; Wegener's granulomatosis

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ENZYME ANTIBODY; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; PROTEINASE 3 ANTIBODY; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; BONE MARROW TOXICITY; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUNG ABSCESS; LUNG ASPERGILLOSIS; LUNG LOBECTOMY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINASE INHIBITION; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SPIROMETRY; SUBDURAL HEMATOMA; WEGENER GRANULOMATOSIS;

EID: 72149114513     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306400903010094     Document Type: Review

References (29)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-8.
3. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
4. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
5. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40 : 2187-98.
6. Reinhold-Keller E, Fink COE, Herlyn K, Gross WL, de Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-32.
7. de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9.
8. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-73.
9. Jayne D, Rasmussen N, Andrassy K, et al. A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New Engl J Med 2003; 349: 36-44.
10. García Hernández FJ, Ocaña Medina C, González León R, et al. Utilidad del rituximab en el tratamiento de pacientes con enfermedades sistémicas autoinmunitarias. Med Clin (Barc) 2007; 128: 458-62.
11. Specks U, Fervenza FC, McDonald TJ, Hogan MCE. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40.
12. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-8.
13. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
14. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary responses. Scand J Rheumatol 2005; 34: 229-32.
15. Keogh K, Ytterberg SR, Fervenza F, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis. Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
16. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8.
17. Tamura N, Matsudaira R, Hirashima M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007; 46: 409-14.
18. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25: S23-S7.
19. Stasi R, Stipa E, del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006; 45: 1432-6.
20. Henes JC, Fritz J, Koch S, et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis -additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007; 26: 1711-5.
21. Sánchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N. Effect of rituximab on refractory Wegener's granulomatosis with predominant granulomatous disease. J Clin Rheumatol 2008; 14: 92-3.
22. Wong CF. Rituximab and antineutrophil cytoplasmic antibodyassociated vasculitis. Granulomatous disease more resistant than vasculitis disease?. J Clin Rheumatol 2008; 14: 61-4.
23. Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005; 20: 622-5.
24. Bachmeyer C, Cadranel JF, Demontis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. 2005; 20: 1274.
25. th Annual Scientific Meeting. Washington, November 2006; Abstract 1265.
26. th June 2009, in: http://www.vasculitis.org/ protocols/ RITUXVAS.pdf
27. th June 2009, in: http://www.immune tolerance.org/RAVE
28. th June 2009, in: http://www.clinicaltrials.gov/ct2/show/NCT003 07593
29. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35: 2017-23.